Objective-To investigate whether an intravenously injected cathepsin-B activatable theranostic agent (L-SR15) would be cleaved in and release a fluorescent agent (chlorin-e6) in mouse atheromata, allowing both the diagnostic visualization and therapeutic application of these fluorophores as photosensitizers during photodynamic therapy to attenuate plaquedestabilizing cathepsin-B activity by selectively eliminating macrophages. Approach and Results-Thirty-week-old apolipoprotein E knock-out mice (n=15) received intravenous injection of L-SR15 theranostic agent, control agent D-SR16, or saline 3× (D0, D7, D14). Twenty-four hours after each injection, the bilateral carotid arteries were exposed, and Cy5.5 near-infrared fluorescent imaging was performed. Fluorescent signal progressively accumulated in the atheromata of the L-SR15 group animals only, indicating that photosensitizers had been released from the theranostic agent and were accumulating in the plaque. After each imaging session, photodynamic therapy was applied with a continuous-wave diode-laser. Additional near-infrared fluorescent imaging at a longer wavelength (Cy7) with a cathepsin-B-sensing activatable molecular imaging agent showed attenuation of cathepsin-B-related signal in the L-SR15 group. Histological studies demonstrated that L-SR15-based photodynamic therapy decreased macrophage infiltration by inducing apoptosis without significantly affecting plaque size or smooth muscle cell numbers. Toxicity studies (n=24) showed that marked erythematous skin lesion was generated in C57/BL6 mice at 24 hours after intravenous injection of free chlorin-e6 and ultraviolet light irradiation; however, L-SR15 or saline did not cause cutaneous phototoxicity beyond that expected of ultraviolet irradiation alone, neither did we observe systemic toxicity or neurobehavioral changes. Conclusions-This is the first study showing that macrophage-secreted cathepsin-B activity in atheromata could be attenuated by photodynamic therapy using a protease-mediated theranostic agent. (Arterioscler Thromb Vasc Biol. 2013;33:1360-1365.)
M atrix-disorganizing proteases, such as cathepsins or matrix metalloproteinases from macrophages, can destabilize atheromata, followed by plaque rupture to cause thromboembolic stroke or myocardial infarction. [1] [2] [3] [4] We previously showed that molecular imaging of cathepsin-B (CatB) or matrix metalloproteinase-2/9 protease activity reflected the inflammatory component of atherosclerotic pathology in mice 5 and human atheromata. 6 We also showed that the protease imaging could quantitatively demonstrate plaque-stabilizing effects of antiatherosclerotic drugs 5 and exercise training 7 in mice.
The principle of photodynamic therapy (PDT) is to kill unwanted cells by using a combination of photosensitizers and light illumination to generate highly reactive oxygen species that locally destroys cells over short diffusion distances. [8] [9] [10] A recent PDT study using macrophage-targeted photosensitizers preliminarily demonstrated the viability of near-infrared lightactivated therapeutic nanoagents in the treatment of atherosclerotic vascular disease by showing preferential destruction of macrophages in vitro and in mouse atheromata. 11 Choi et al 12 developed a novel protease-mediated photodynamic agent that allowed visualization of targets and local drug concentration before exerting selective antitumor effects on light illumination: L-SR15 CatB activatable photosensitizers that are nontoxic in their native state but become fluorescent and produce singlet oxygen on protease conversion followed by light therapy. In our recent study, using the RAW 264.7 macrophage cell line, we showed that intracellular uptake of L-SR15 and subsequent activation of the theranostic nanoagent by proteolytic cleavage could induce cell death on light illumination; the macrophage cell death was interfered by commonly prescribed cardiovascular drugs with antioxidant effects: atorvastatin and clopidogrel. 13 There is great need for the technologies of PDT and activatable theranostic agents to be applied in a suitable animal model, allowing us to assess whether protease-activated smart probes can be used to target photosenitizers to plaque macrophages and eliminate these cells and their inflammatory enzyme secretions.
In the present study, we hypothesized that (1) intravenously injected L-SR15 could be accumulated and activated in mouse atheromata, allowing for the visualization of inflammatory targets, (2) subsequent light treatment could kill macrophages and (3) consequently decrease CatB protease activity within the vulnerable atheromata. A dual-channel in vivo near-infrared fluorescent (NIRF) imaging was performed to detect Cy5.5 signal from the activated L-SR15 theranostic nanoagents and Cy7 CatB-related signal in atheromatous carotid arteries and aortas of apolipoprotein E (apoE) knock-out (apoE −/− ) mice.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

In Vivo Cy5 NIRF Imaging Showed Increased Fluorescent Signal in the Carotids of apoE −/− Mice, Indicating That Intravenously Injected L-SR15 Smart Photosensitizer Was Activated in the Carotid Atheromata
Serial in vivo Cy5.5 NIRF imaging was performed in the same animals 24 hours after the intravenous injection of L-SR15 3× for 2 weeks (days 1, 8, and 15) and 1 week after the last injection ( Figure 1 ). Compared with the saline group, there was a progressive increase in fluorescent signal localized to the carotid arteries (P=0.011, repeated-measures ANOVA) in the L-SR15 group (P<0.001, Dunnett post hoc test), which was not the case in the D-SR16 (chlorin-e6 [Ce6]-conjugated poly(ethylene glycol)-graft-poly(D-lysine) not cleaved by proteases) group (P=0.304; Figure 2A ). This reflects more efficient and target-specific cleavage-activation of L-SR15 by CatB and consequently higher reactive oxygen species-generating potential of L-SR15 on light illumination compared with noncleaved D-SR16 and saline controls.
In Vivo CatB Activity Was Significantly Reduced by PDT in Animals Receiving L-SR15
In vivo Cy7 NIRF imaging was performed at days 1 and 22 after the intravenous injection of L-SR15 3× for 2 weeks, each followed by light therapy. As shown in Figure 2B , compared with the saline group, there was a decrease in fluorescent signal in the carotid arteries (P<0.001, repeated-measures ANOVA) not only in the L-SR15 group but also in the D-SR16 group (P=0.001 and 0.017, respectively; Dunnett post hoc tests). Ex vivo Cy7 NIRF imaging ( Figure 3 ) confirmed that CatB-related NIRF signal intensities were significantly lower (P=0.018, ANOVA) in the carotid arteries of L-SR15 group versus saline group (P=0.010, Dunnett post hoc test), which however was not the case in the D-SR16 group (P=0.143). There was no significant intergroup difference in the aortas for which no PDT had been applied.
L-SR15-Based PDT Induced Apoptosis of Macrophages Without Affecting Plaque Size or Smooth Muscle Cell Numbers in Carotid Atheromata of ApoE −/− Mice
As shown in the histological staining of carotid atheroma sections from representative animals that were euthanized after 3 PDTs ( Figure 4 ), terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling-positive macrophages were more frequently observed in the L-SR15 group compared with the D-SR16 group or saline group. Unlike animals in the latter groups, in 2 of the 5 histology-examined animals in the L-SR15 group Mac-3 immunoreactivity was rarely observed (≈0.5% of the total area of the carotid tissue; Figure I in the online-only Data Supplement). Thus, the extent of CatB immunoreactivity was relatively small in the L-SR15 group. Compared with the saline group, quantification of the histological data ( Figure 5 ) did show that Mac-3 and CatB immunoreactivity was less extensive, and that terminal deoxynucleotidyl transferasemediated deoxyuridine triphosphate nick end labeling positivity was more extensive in the L-SR15 group (P=0.009, 0.009, and 0.016, respectively; Kruskal Wallis ANOVA with Mann-Whitney post hoc tests), which was not the case in the D-SR16 group (all P>0.05). In the L-SR15 group, some smooth muscle cells near terminal deoxynucleotidyl transferasemediated deoxyuridine triphosphate nick end labeling-positive macrophages were also terminal deoxynucleotidyl transferasemediated deoxyuridine triphosphate nick end labeling-positive, 
In Vivo CatB Activity Was Not Attenuated in Carotid Atheromata by One-Time PDT Using L-SR15
Twenty-four hours after L-SR15 and Prosense 750 (D1), in vivo Cy5.5 imaging did not show significantly high NIRF signal in the carotid arteries of the L-SR15 group animals, when compared with the D-SR16 or saline group animals ( Figure VI in the online-only Data Supplement). In vivo Cy7 imaging did not show significant intergroup differences in the CatB-related NIRF signal intensity. At D3 or D22, 24 hours after an additional injection of Prosense 750, Cy5.5 and Cy7 NIRF imaging showed no significant intergroup differences, either. Ex vivo NIRF imaging confirmed this ( Figure VI 
L-SR15 Did Not Show Systemic/Neurobehavioral Toxicity or Cutaneous Phototoxicity
At 24 hours after the intravenous injection of saline, L-SR15, or free Ce6 and ultraviolet light irradiation (14.9 J/cm 2 ), the median area of erythema attributable to phototoxicity was larger in the Ce6 group than in the L-SR15 group (P=0.024; Figure 6 ). There was no significant difference between the saline group and the L-SR15 group. At lower irradiation intensities, skin phototoxicity did not differ significantly between groups, although there was an overall difference at ultraviolet light intensity 11.2 J/cm 2 (P=0.049) with a trend of relatively wider photodamage in the Ce6 group compared with the other groups. Except for slightly elevated aspartate aminotransferase levels in the Ce6 group, hematologic studies showed no noticeable systemic toxicity in all groups ( Table I in the onlineonly Data Supplement). In a different set of animals, significant neurobehavioral toxicity 14 was not observed during the 3 weeks after intravenous injection of L-SR15 versus D-SR16 or saline (Table II in 
Discussion
In this study, we used a protease-mediated theranostic photodynamic agent to show the following: (1) intravenously injected L-SR15 photosensitizers were cleaved in and released photosensitizing fluorophores in the carotid atheromata of 30-weekold apoE −/− mice fed on a Western diet, (2) PDT in the presence of these released fluorophores served to reduce plaque CatB activity, and (3) PDT resulted in relatively selective apoptotic attenuation of macrophages within the atheromata, without significantly affecting plaque size or smooth muscle cell numbers. Free Ce6 induced photodamage in the skin with ultraviolet exposure, consistent with its systemic photosensitizing nature, but L-SR15 did not cause either cutaneous phototoxicity nor systemic or neurobehavioral toxicity, consistent with controlled local release of photosensitizer in this agent.
Plaque-destabilizing proteases, such as CatB 3,5,15 from macrophages, are the same enzymes needed for cleavage activation of L-SR15 photosensitizers, 12 allowing the selective release of photosensitizer near the CatB-secreting macrophages, their subsequent targeting by PDT to generate reactive oxygen species that are active only over short diffusion distances, and consequently selective destruction of inflammatory cells within the atheromas. This would predict, and we have observed, that smooth muscle cells and collagen fibers in the media would be largely left unscathed by PDT, thereby contributing to plaque stabilization. 16 The repeated L-SR15-based PDT did not decrease the plaque size; and this kind of functional versus anatomic discrepancy in atherosclerosis pathogenesis is in line with our previous study on antiatherosclerotic effects of exercise 7 : treadmill exercise could effectively reduce aortic matrix metalloproteinase activity in mice with preexisting atheromata despite the continued high-fat diet and plaque growth. It should also be considered that the relatively short treatment time (3 weeks) may have not allowed us to observe further regression of established plaques that might have occurred at a later time. 17 Instead of an intravenous injection of L-SR15 followed by one-time light illumination, repetitive L-SR15-based PDTs were required for a relatively strong activation of the smart photosensitizers and high CatB-reducing antiatherosclerotic effects. It seems to have taken some time for sufficient quantity of L-SR15 to enter the carotid atheromata and there get activated. However, once present, photosensitizing fluorophores did not diffuse out rapidly from the plaque, as evidenced by accumulation after weekly dosing. The fluorescence observed in the plaque is a complex function of the following: (1) delivery of nonactivated L-SR15 to the plaque, (2) cleavage activation by local proteases, and (3) clearance of these fluorescent products from the plaque. Although some of these steps are well understood, the net effect on pharmacokinetics and pharmacodynamics of all these steps acting in synergy is currently unknown. Clearly, our data indicate that the simple model of a small molecule diffusing away and clearing is incorrect. Hypotheses to explain the observation might include the following: (1) increased delivery to plaque over longer times than expected by circulating L-SR15, (2) ongoing protease-mediated activation over a slower time course than anticipated, and (3) retention of the activated fluorescent compounds in the plaque by either biological (phagocytosis by macrophages), chemical (an as yet unkown fixation reaction), or physical (a diffusion barrier out of lipid-filled plaques) means. Modeling of precise drug kinetics would be an important factor to study in the future, to shed light on the dosing and timing of the agent when used in clinic.
It should be noted that atherosclerosis is a progressive and cumulative disease 18 for which an acute cure might be unrealistic. A repetitive long-term suppression of inflammatory cell populations might be an acceptable way to manage the disease. L-SR15-based PDT has significant translational potential in the atherosclerosis clinic, considering that prolonged administration of effective concentrations of conventional photosensitizers is usually not possible because of doselimiting systemic phototoxicities. 9, 10, 12, 19 The combination of intravenous L-SR15 injection and focal light illumination may serve as an effective treatment to avoid unnecessary side effects with reduced phototoxicity, given the quenched state of the native compounds. 12 In addition, this theranostic approach could be used to tailor treatments, 20 such as preintervention or presurgical detection and stabilization of inflammatory plaques that are prone to protease-mediated rupture and thromboembolic complications, which could potentially be provoked by the procedure itself.
Our study has limitations. First, we surgically exposed the carotid arteries for imaging and PDT in a mouse atherosclerosis model. Repeated dissection of pericarotid tissues may have resulted in inflammation in the carotid arteries, although between day 0 and day 21, we observed no significant difference in the CatB-related Cy7 NIRF signal intensities in the carotid arteries of control animals, suggesting that pericarotid inflammatory change did not extend to the media. Clinically, a catheter-based system might be able to see and treat vulnerable plaques, where high matrix-disorganizing proteolytic activity is present. 11 This approach might work in all vessels and might be the only approach in the deeper vasculature, for which surface access by photons is not feasible. However, a catheter-based approach is invasive, and may not allow for repeated treatments. Using longer wavelength photosensitizers (>750 nm) with improved light penetration properties may allow noninvasive external irradiation in superficial vasculatures, such as the carotid artery. If this is successful at stabilizing plaque, and preventing ischemic stroke, a major cause of death and disability worldwide could be treated with a new modality of treatment. CatB molecular imaging based on the diagnostic capability of L-SR15, combined with conventional anatomic imaging, such as ultrasonography and angiography, 6 could help identify unstable target plaques with high-proteolytic enzyme activity. Second, the control compound D-SR16 also reduced CatB-related NIRF signal intensities in vivo, although the subsequent ex vivo imaging demonstrated that only L-SR15 reduced the CatB activity. As was previously reported, 12 intact (ie, noncleaved) L-SR15 or D-SR16 conjugates could generate some degree of singlet oxygen molecules on light treatment: ≈13% of the amount of singlet oxygen generated by free Ce6. Thus, D-SR16 could also have produced some low-level phototoxic effects. Third, further studies on bystander apoptotic effects of the protease-mediated PDT are required to confirm whether Ce6 photosensitizers released from macrophage-activated L-SR15 could diffuse out to damage nearby smooth muscle cells on light therapy. Finally, we did not include such control groups as saline with light therapy or L-SR15 without light therapy, because it seemed unlikely to us that these comparisons would teach us much, and would add much to the expense of our study.
In conclusion, we show that plaque-destabilizing CatB activity could be attenuated by PDT using L-SR15, a molecularly targeted protease-mediated photodynamic theranostic agent. This study provides proof-of-principle that molecular targeting of plaque macrophages is possible with a see-andtreat approach.
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